Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Update

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,750,000 shares, an increase of 6.1% from the October 15th total of 1,650,000 shares. Based on an average trading volume of 276,800 shares, the days-to-cover ratio is currently 6.3 days.

Analysts Set New Price Targets

A number of brokerages have issued reports on EYEN. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research note on Tuesday, November 14th. William Blair reaffirmed an “outperform” rating on shares of Eyenovia in a research note on Wednesday, November 1st. Finally, Brookline Capital Management assumed coverage on shares of Eyenovia in a report on Tuesday, October 17th. They issued a “buy” rating and a $8.00 target price on the stock.

Eyenovia Trading Up 3.9 %

EYEN opened at $1.34 on Friday. The firm’s fifty day moving average is $1.45 and its two-hundred day moving average is $2.18. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.73 and a current ratio of 4.05. The firm has a market cap of $59.12 million, a PE ratio of -2.03 and a beta of 1.75. Eyenovia has a twelve month low of $1.05 and a twelve month high of $5.85.

Institutional Investors Weigh In On Eyenovia

Hedge funds have recently bought and sold shares of the company. Meitav Investment House Ltd. acquired a new stake in Eyenovia in the second quarter worth $1,104,000. Two Sigma Securities LLC acquired a new stake in shares of Eyenovia during the second quarter worth $27,000. Goldman Sachs Group Inc. acquired a new stake in shares of Eyenovia during the second quarter worth $28,000. American International Group Inc. acquired a new stake in shares of Eyenovia during the second quarter worth $32,000. Finally, Leo Brokerage LLC acquired a new stake in shares of Eyenovia during the first quarter worth $57,000. 16.66% of the stock is currently owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.